Group 1 - The core focus of the news is the recent institutional research conducted on Innovation Medical Management Co., Ltd., highlighting the advancements and product offerings of its subsidiary, Bole Brain Machine [1][2] - The research event took place on September 25, with participation from eight institutions, including Guohai Securities and Dongwu Securities, showcasing the company's commitment to transparency and engagement with investors [1] - Bole Brain Machine's C-end product, Cyberlink AC5, features user-friendly design and advanced brain-machine interface technology, aimed at improving the quality of life for patients with motor impairments [1][2] Group 2 - Clinical trials for the medical version of Bole Brain Machine's products are progressing well, with over 100 patient tests completed, showing significant improvements in motor function for both new and long-term patients [2] - The C-end product weighs 1.5 kg and includes two batteries with a six-hour lifespan each, designed for daily use and convenience for patients [2] - Future product development includes plans for lower limb rehabilitation products and a focus on invasive technology routes, with ongoing research into intelligent peripheral nerve stimulation systems [2][3] Group 3 - The C-end product is priced based on the value it provides to hemiplegic patients, potentially saving families 40,000 to 60,000 yuan annually in the Jiangsu, Zhejiang, and Shanghai regions [3] - Innovation Medical holds a 68.356% stake in Bole Brain Machine, which is included in the company's consolidated financial statements, indicating a strong financial interest in the subsidiary's success [3]